Regulation A Offering Now Open
Leading The Transition To Better Smoking And Vaping Alternatives
Cabbacis is a publicly traded company (OTCQB: CABI) developing iBlend™ cigarettes and vaporizer pods with approximately 95 percent reduced-nicotine tobacco and hemp which became federally legal in 2018.
Backed by a global patent portfolio including 36 issued patents, the company is positioned to scale within the expanding reduced-risk tobacco category.
$250 USD Minimum Investment
$250 USD Minimum Investment
Overview
Built On Patents, Regulation, And Market Demand
Publicly traded on OTCQB under ticker CABI
36 issued patents worldwide with additional applications pending
Products developed within established tobacco regulatory frameworks
Focused on tobacco harm reduction
Offering type: Regulation A
Security: Common equity
Current share price: $2.00 per share
Minimum investment: $250
Industry: Tobacco harm reduction products
Product focus: Very-low-nicotine cigarettes and vapor products
The Opportunity
Why The Smoking And Vaping Market Is Changing
The global tobacco market is undergoing a structural shift. Regulators, consumers, and manufacturers are increasingly focused on reducing harm and nicotine exposure while maintaining adult consumer demand.
Traditional cigarettes face mounting regulatory pressure. At the same time, many adult smokers are seeking alternatives that do not require abandoning familiar smoking formats.
This transition is still in its early stages, creating an opportunity for companies positioned with differentiated products and defensible intellectual property.
Focused On Tobacco Harm Reduction
What Cabbacis Does
Cabbacis is a tobacco product manufacturer focused on developing and commercializing harm-reduction products for adult smokers.
The company’s approach centers on:
Approximately 95% reduced-nicotine tobacco
Federally legal, non-intoxicating hemp
Familiar cigarette and vapor formats
Patented products
The objective is straightforward. Reduce nicotine content while otherwise preserving adult consumer acceptance.
The iBlend™ Product Line
Built For Familiarity And Scale
Cabbacis is commercializing two primary product formats.
iBlend™ Cigarettes
Very-low-nicotine cigarettes designed to closely resemble traditional smoking experiences
Significantly lower nicotine content
iBlend™ Vaporizer Pods
Vapor products delivering the same proprietary blend
Modern, regulated format aligned with evolving consumer preferences
Both formats are designed to integrate into existing tobacco distribution and regulatory frameworks.
Why Our Approach Matters
Structural Tailwinds Support Adoption
Increasing regulatory focus on nicotine addiction
Growing consumer interest in reduced-risk alternatives
Demand for familiar formats rather than those forcing radical behavioral changes
Limited competition due to company’s patented products
Cabbacis operates where regulation, consumer demand, and innovation intersect.
Intellectual Property
A Defensible Patent Portfolio
Cabbacis holds a substantial global intellectual property position, including:
36 issued patents worldwide
Multiple pending patent applications
Protection across formulations and delivery methods
This patent base supports long-term differentiation, licensing potential, and strategic flexibility.
Market Opportunity
A Large Market In Transition
Tobacco and nicotine products represent a global market measured in the hundreds of billions of dollars annually.
As nicotine reduction and harm-reduction initiatives gain momentum, even modest adoption of alternative products represents a meaningful revenue opportunity.
Cabbacis is positioned to participate in this shift without relying on mass behavioral change.
Product And Commercialization Roadmap
A Clear Path To Scale
Cabbacis is advancing iBlend™ products through upcoming staged commercialization while expanding intellectual property and distribution opportunities.
Near Term
Advance commercialization of iBlend™ cigarettes and vaporizer pods
Expand manufacturing and supply chain readiness
Continue regulatory engagement and market entry planning
Mid Term
Broaden distribution through strategic partners
Explore worldwide licensing opportunities
Support and expand patent coverage and product variations
Long Term
Scale international market presence
Monetize intellectual property through partnerships and licensing
Build a diversified portfolio of reduced-risk tobacco products
Business Model
Multiple Paths To Growth
The company plans to pursue growth through:
Direct product commercialization
Strategic partnerships
Licensing arrangements
Geographic expansion
Invest in Better Smoking and Vaping Alternatives
Use Of Proceeds
Planned Capital Deployment
Proceeds from the Regulation A offering are expected to support:
Manufacturing and supply chain expansion
Product commercialization and distribution
Ongoing intellectual property development
General corporate purposes
Investment Highlights
Why Investors Are Paying Attention
Exposure to a regulated category undergoing structural change
Clear focus on tobacco harm-reduction products
Patented and differentiated products
Scalable cigarette and vapor formats
Public company transparency
Accessible minimum investment
This offering provides investors the opportunity to participate in an evolving and growing segment of the tobacco market.
get in touch
Let's talk about your investment
Get in touch with the Cabbacis team to learn more about the investment opportunity or to ask any questions you may have. We’re here to help!
Frequently Asked Questions (FAQs)
1. What is Cabbacis?
Cabbacis is a tobacco product manufacturer focused on commercializing harm-reduction products – led by the flagship iBlend™ cigarettes and iBlend™ vaporizer pods which are covered by 36 international patents.
2. What does the company develop?
Cabbacis develops products containing very-low-nicotine tobacco and hemp that smoke or vape just like conventional products.
3. What is the purpose of these products?
To provide adult consumers with alternatives to traditional tobacco to help smokers smoke less, reduce nicotine dependence & exposure, and increase quit attempts.
4. What are the key product categories?
Very-low-nicotine cigarettes and vaporizer pods.
5. What is the primary brand name?
The company’s consumer-facing brand is “iBlend.”
6. What makes iBlend products different?
iBlend uses patented formulations of very-low-nicotine tobacco and hemp which offer pleasing taste and sensory characteristics with 95 percent less nicotine.
7.Are the products currently on the market?
Products have been developed and manufactured. Commercial sales have not yet begun.
8. Are the products regulated as tobacco or cannabis?
For sales in the United States, the products are regulated by the U.S. Food and Drug Administration (FDA) as tobacco products and some states may regulate the products as cannabis products.
9. Has the company conducted consumer testing?
Yes. Consumer testing has been conducted to refine formulations and validate market interest.
10. Does the company operate any retail locations?
No. Distribution will occur through traditional wholesale and selected retail channels.
11. Does Cabbacis own patents?
Yes. The company holds 36 international patents on its products.
12. What areas are covered by the patents?
Cigarettes and vaporizer pods essentially covering any combination very-low-nicotine tobacco and hemp.
13. Does the company license any technology?
Yes. Cabbacis in-licenses the proprietary very-low nicotine tobacco it uses in its products from North Carolina State University.
14. What is the company’s IP strategy?
The company has built a broad patent portfolio that covers it’s iBlend™ products internationally.
15. Has Cabbacis conducted clinical studies?
Cabbacis contracted the Rose Research Center to carry out a pilot clinical trial on 16 smokers exclusively using four types of very-low-nicotine tobacco cigarettes made by Cabbacis during 3-hour ad libitum use sessions, which followed overnight abstinence from their usual brand cigarette. The nicotine content of all types was reduced by approximately 95 percent, as compared to the average of mainstream American brands. Three iBlend™ cigarette types contained very-low-nicotine tobacco and each type had a different level of hemp (5%, 10% and 20%), and the fourth cigarette type contained very-low-nicotine tobacco without any hemp.
16. What were the study results?
Participants across all four cigarette types reported a significant reduction in craving for their usual brand of cigarettes which was sustained over the 3-hours of ad libitum use of the study cigarettes. All four Cabbacis cigarette types were rated higher for satisfaction on the standardized mCEQ questionnaire than has been previously reported in the literature with other 95-percent reduced-nicotine cigarettes.
17. Does the company plan further studies?
Yes. The company is planning 2 follow-up behavioral studies and a consumer-perception study.
18. What market is Cabbacis targeting?
The global market for smoking and vaping alternatives.
19. What is the size of the total addressable market?
The global tobacco market exceeds $900 billion and the U.S. market exceeds $100 billion.
20. Who are the company’s competitors?
Traditional tobacco companies and smoking cessation companies.
21. What makes Cabbacis different?
Patent-protected tobacco products with hemp which exactly replicate the ritual and experience of smoking or vaping.
22. What is the company’s go-to-market strategy?
Wholesale distribution, direct-to-consumer e-commerce, and select retail partnerships.
23. What is being offered to investors?
Equity shares in Cabbacis Inc under a Regulation A (Tier 2) offering.
24. Is this offering qualified by the SEC?
Yes. The SEC qualified the Offering Circular on November 24, 2025.
25. What is the price per share?
$2.00 per share.
26. What is the minimum investment?
$250.00.
27. Who can invest?
Any U.S. resident over 18 can invest, subject to Regulation A limits. International investors may participate where permitted.
28. Is there a maximum investment for some individuals?
Yes. Non-accredited investors are limited to 10 percent of their annual income or net worth, whichever is greater. There is no limit for accredited investors.
29. What is the maximum total raise?
Up to $7.5 million in gross proceeds.
30. Are shares freely tradeable after purchase?
Yes. Shares are listed on the OTCQB market under the symbol, CABI; however, the shares are currently very thinly traded.
31. Is the company profitable?
No. Cabbacis is a pre-revenue, early-stage company; however, the company has a very low burn rate.
32. How will investor funds be used?
The funds are expected to be for at least a 2-year period and will be used for G&A, R&D, Regulatory Expenses, Tobacco and Hemp Plantings, IP and machinery as detailed in the Offering Circular.
33. Are financial statements available?
Yes. Audited financial statements are included in the Offering Circular.
34. Will existing members or founders sell shares in this offering?
No. All proceeds go to the company. No insiders are selling shares.
35. Will investors receive updates?
Yes. Investors will receive periodic updates via email and through the investment portal.
36. Will I receive dividends?
No. The company does not expect to pay dividends in the near term.
37. What type of legal entity is Cabbacis?
Cabbacis Inc (OTCQB: CABI) is a Nevada corporation and its wholly-owned operating company, Cabbacis LLC, is a New York company.
38. Will investors receive K-1s or 1099s?
The company does not expect to issue K-1s or 1099s.
39. Can I invest through an IRA, trust, or LLC?
Yes. Cabbacis may accept investments from self-directed IRAs, trusts, and other legal entities.
40. Can international investors participate?
Yes, where permitted under U.S. and local laws.
41. Will I have voting rights?
Investor rights are defined in the company’s governing documents. Regulation A investors may have limited governance rights.
42. How do I track my investment?
You will receive email confirmations and updates via the investment portal.
43. What is the expected holding period?
This is up to you, but please keep in mind that Cabbacis shares may be illiquid on the OTCQB market for an extended period of time.
44. Will my investment be listed in a brokerage account?
No. Shares are initially held electronically through the transfer agent or issuing platform.
45. Is this a crowdfunding campaign?
No. This is a Regulation A offering, not a Regulation CF (crowdfunding) raise.
46. Has Cabbacis raised money before?
Yes. The company has previously raised capital through private offerings and a Regulation A offering that was qualified by the SEC in November 2023. The CEO has invested over $1.5 million in the company since inception.
47. Who do I contact with investment questions?
The investor relations team and platform support are available through the company’s investment portal.
48. Will I be diluted in the future?
Yes. Future equity financing could dilute existing investors.
49. Can I lose my entire investment?
Yes. This is a high-risk investment and may result in total loss of capital.
50. How is the $2.00 share price determined?
It reflects a pre-money valuation set by the company. It is not based on a third-party appraisal.
51. Are there commissions or fees for investors?
No commissions are charged directly to investors although commissions are charged for investments that go through the company’s investment bank. These and the offering expenses are paid by the company.
52. Is there a transfer agent?
Yes. A registered transfer agent manages investor records and share issuances.
53. Where can I read the Offering Circular?
It is available on the company’s investment portal and on SEC.gov under Cabbacis.
Ready to Invest?
Contact Us
Legal
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities by Cabbacis Inc. is made pursuant to Regulation A under the Securities Act of 1933, as amended, and only through an offering circular that has been qualified by the U.S. Securities and Exchange Commission.
An offering circular relating to the securities has been filed with the SEC and includes important information about the Company, its business operations, financial condition, management, capitalization, use of proceeds, and material risk factors. Prospective investors should read the offering circular in its entirety before making any investment decision. In the event of any inconsistency between this communication and the offering circular, the information contained in the offering circular controls.
Investing in securities involves a high degree of risk, including the possible loss of all invested capital. There is no guarantee of any return, liquidity event, or future performance. Securities offered pursuant to Regulation A are speculative, illiquid, and not suitable for all investors. Past performance, if referenced, is not indicative of future results. Statements regarding future plans, expectations, or performance are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially.
Neither the U.S. Securities and Exchange Commission nor any state securities regulator has approved or disapproved of these securities or passed upon the adequacy or accuracy of this communication. Any representation to the contrary is a criminal offense.
Copyright 2026. Cabbacis Inc.. All Rights Reserved.